<PAGE> 1
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
FILED BY THE REGISTRANT [X] FILED BY A PARTY OTHER THAN THE
REGISTRANT [ ]
------------------------------------------------------------------------
Check the appropriate box:
[ ] Preliminary Proxy Statement
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-2
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
BioSphere Medical, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.
1. Title of each class of securities to which transaction applies:
2. Aggregate number of securities to which transaction applies:
3. Per unit price or other underlying value of transaction computed
pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
4. Proposed maximum aggregate value of transaction:
5. Total fee paid:
[ ] Fee paid previously with preliminary materials:
[ ] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by
registration statement number, or the form or schedule and the date
of its filing.
1. Amount previously paid:
2. Form, Schedule or Registration Statement No.:
3. Filing Party:
4. Date Filed:
------------------------------------------------------------------------
<PAGE> 2
Biosphere Corporate Logo
May 1999
Dear Shareholder,
I'd particularly like to encourage you to come to the Annual Meeting this
year to hear first hand about the many changes we have made. While I address
them in my Letter in the enclosed Annual Report, let me briefly summarize them:
...your Board of Directors decided that a complete change in business
strategy was the best way to enhance our potential for creating
shareholder value
...our chromatography business was sold in its entirety for cash
...the proceeds from the sale will launch a medical device company
...the Company's name changed to BioSphere Medical, Inc. to reflect the
nature of the new business
...an experienced medical device industry executive, John Carnuccio, was
named President & CEO
...our trading symbol changed to BSMD (on the OTC Bulletin Board) to alert
investors to these changes
At the Annual Meeting, I'd like to personally introduce John to you and
have him tell you about our business strategy, our products and our outlook. I
hope you'll come away with a feeling of optimism!
Sincerely,
/s/ Jean-Marie Vogel
Jean-Marie Vogel
Chairman
<PAGE> 3
BIOSPHERE MEDICAL, INC.
111 LOCKE DRIVE
MARLBOROUGH, MASSACHUSETTS 01752
NOTICE OF 1999 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 16, 1999
The 1999 Annual Meeting of Stockholders of BioSphere Medical, Inc. (the
"Company") will be held at Hale and Dorr LLP, 60 State Street, Boston,
Massachusetts, on Wednesday, June 16, 1999 at 2:00 p.m., local time, to consider
and act upon the following matters:
1. To set the number of directors at eight and to elect eight directors to
serve until the next Annual Meeting of Stockholders.
2. A proposal to approve and adopt an amendment to the Company's
Certificate of Incorporation to increase the number of authorized shares
of Common Stock, par value $.01 per share, of the Company from
12,000,000 to 25,000,000.
3. A proposal to approve and adopt an amendment to the Company's 1997 Stock
Incentive Plan to increase the number of shares of Common Stock reserved
for issuance thereunder from 1,000,000 to 3,150,000.
4. To transact such other business as may properly come before the meeting
or any adjournment thereof.
Stockholders of record at the close of business on May 10, 1999 are
entitled to notice of, and to vote at, the meeting. The stock transfer books of
the Company will remain open for the purchase and sale of the Company's Common
Stock.
All stockholders are cordially invited to attend the meeting.
By Order of the Board of Directors,
PHILIP V. HOLBERTON, Secretary
Marlborough, Massachusetts
May 26, 1999
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE AND
SIGN THE ENCLOSED PROXY CARD AND PROMPTLY MAIL IT IN THE ENCLOSED ENVELOPE IN
ORDER TO ASSURE REPRESENTATION OF YOUR SHARES AT THE MEETING. NO POSTAGE NEED BE
AFFIXED IF THE PROXY CARD IS MAILED IN THE UNITED STATES.
<PAGE> 4
BIOSPHERE MEDICAL, INC.
111 LOCKE DRIVE
MARLBOROUGH, MASSACHUSETTS 01752
PROXY STATEMENT FOR THE 1999 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 16, 1999
This Proxy Statement is furnished in connection with the solicitation of
proxies by the Board of Directors of BioSphere Medical, Inc. ("BioSphere
Medical" or the "Company") for use at the 1999 Annual Meeting of Stockholders to
be held on June 16, 1999 and at any adjournment or adjournments of that meeting.
All proxies will be voted in accordance with the instructions contained therein,
and if no choice is specified, the proxies will be voted in favor of the matters
set forth in the accompanying Notice of Meeting. Any proxy may be revoked by a
stockholder at any time before it is exercised by delivery of written revocation
to the Secretary of the Company.
The Company's Annual Report for the year ended December 31, 1998 is being
mailed to stockholders with the mailing of this Notice and Proxy Statement on or
about May 26, 1999.
A COPY OF THE COMPANY'S ANNUAL REPORT ON FORM 10-K, AS AMENDED BY A FORM
10-K/A, FOR THE YEAR ENDED DECEMBER 31, 1998, AS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION, EXCEPT FOR EXHIBITS, WILL BE FURNISHED WITHOUT CHARGE TO
ANY STOCKHOLDER UPON WRITTEN REQUEST OF THE SECRETARY, BIOSPHERE MEDICAL, INC.,
111 LOCKE DRIVE, MARLBOROUGH, MASSACHUSETTS 01752.
VOTING SECURITIES AND VOTES REQUIRED
On May 10, 1999, the record date for the determination of stockholders
entitled to notice of and to vote at the meeting, there were outstanding and
entitled to vote an aggregate of 8,456,059 shares of Common Stock of the
Company, $.01 par value per share ("Common Stock"). Each share is entitled to
one vote.
Under the Company's Bylaws, the holders of a majority of the shares of
Common Stock issued, outstanding and entitled to vote on any matter shall
constitute a quorum with respect to that matter at the Annual Meeting. Shares of
Common Stock present in person or represented by proxy (including shares which
abstain or do not vote with respect to one or more of the matters presented for
stockholder approval) will be counted for purposes of determining whether a
quorum is present.
The affirmative vote of the holders of a plurality of votes cast by the
stockholders entitled to vote at the Annual Meeting is required for the election
of directors. The affirmative vote of the holders of a majority of the shares of
Common Stock issued and outstanding on the record date is required for the
approval of the proposed amendment to the Company's Certificate of
Incorporation. The affirmative vote of the holders of a majority of the shares
of Common Stock voting on the matter is required for the approval of each of the
other matters to be voted upon.
Shares which abstain from voting as to a particular matter, and shares held
in "street name" by brokers or nominees, who indicate on their proxies that they
do not have discretionary authority to vote such shares as to a particular
matter, will not be counted as votes in favor of such matter, and will also not
be counted as votes cast or shares voting on such matter. Accordingly,
abstentions and "broker non-votes" on a matter that requires the affirmative
vote of a certain percentage of the votes cast or shares voting on a matter,
such as the election of directors and the approval of the amendment to the 1997
Stock Incentive Plan, have no effect on the voting of such matter.
<PAGE> 5
STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information, as of January 31, 1999
or such later date as is noted, with respect to the beneficial ownership of: (i)
the Company's Common Stock by each person known by the Company to own
beneficially more than 5% of the outstanding shares of Common Stock; and (ii)
the Company's Common Stock and the Common Stock of Sepracor Inc. ("Sepracor
Common Stock"), the parent company of BioSphere Medical ("Sepracor"), by (A)
each director and nominee for director; (B) each executive officer named below
in the Summary Compensation Table under the heading "Compensation of Executive
Officers;" and (C) all directors and executive officers of the Company as a
group.
The number of shares of the Company's Common Stock and Sepracor Common
Stock beneficially owned by each director or executive officer is determined
under the rules of the Securities and Exchange Commission (the "Commission"),
and the information is not necessarily indicative of beneficial ownership for
any other purpose. Under such rules, beneficial ownership includes any shares as
to which the individual has sole or shared voting or investment power and also
any shares which the individual has the right to acquire within 60 days after
January 31, 1999 through the exercise of any stock option or other right. Unless
otherwise indicated, each person has sole investment and voting power (or shares
such power with his or her spouse) with respect to the shares set forth in the
following table. The inclusion herein of any shares deemed beneficially owned
does not constitute an admission of beneficial ownership of those shares.
<TABLE>
<CAPTION>
SHARES OF
BIOSPHERE PERCENTAGE OF SHARES OF
MEDICAL BIOSPHERE SEPRACOR
COMMON MEDICAL COMMON
STOCK COMMON STOCK
BENEFICIALLY STOCK BENEFICIALLY
NAME AND ADDRESS OWNED OUTSTANDING OWNED(1)
- ---------------- ------------ ------------- ------------
<S> <C> <C> <C>
Sepracor Inc. ........................................ 5,369,788 63.5% N/A
111 Locke Drive
Marlborough, MA 01752
Tudor Investment Corporation.......................... 698,000(2) 8.2% 0
600 Steamboat Road
Greenwich, CT 06830
Timothy J. Barberich.................................. 45,000(3) * 864,855(4)
Jean-Marie Vogel...................................... 401,458(5) 4.7% 5,000(6)
William E. Rich, Ph.D. ............................... 57,080(7) * 0
William M. Cousins, Jr. .............................. 19,000(7) * 400
Alexander M. Klibanov, Ph.D. ......................... 22,500(7) * 3,600
Riccardo Pigliucci.................................... 17,000(7) * 0
Paul A. Looney........................................ 19,000(7) * 0
David P. Southwell.................................... 5,000 * 141,736(8)
Egisto Boschetti, Ph.D. .............................. 80,801(9) * 0
Therese Bourdy........................................ 20,200(7) * 0
All directors and executive officers as a group (12
persons)............................................ 703,039(10) 7.4% 1,015,591(11)
</TABLE>
- ---------------
* Represents holdings of less than one percent.
(1) As of January 31, 1999, except for Mr. Barberich, no officer or director of
BioSphere Medical beneficially owned more than 1% of the Sepracor Common
Stock; Mr. Barberich beneficially owned 2.7% of the Sepracor Common Stock
(see footnote 4 below).
2
<PAGE> 6
(2) Based on information furnished to the Company by Tudor Investment
Corporation ("Tudor"). Tudor is the investment adviser of Tudor BVI
Futures, Ltd. ("Tudor BVI") and The Raptor Global Fund Ltd. ("Raptor
Ltd."). The shares of the Company's Common Stock owned by Tudor include
471,450 shares directly beneficially owned by Tudor BVI; 161,348 shares
directly beneficially owned by Raptor Ltd. and 65,202 shares directly
beneficially owned by Tudor Proprietary Trading, LLC, an affiliate of
Tudor. Tudor disclaims beneficial ownership of the shares held by Tudor BVI
and Raptor Ltd. except to the extent of its pecuniary interest in such
shares.
(3) Includes 43,000 shares of the Company's Common Stock which Mr. Barberich
has the right to acquire within 60 days after January 31, 1999 upon
exercise of outstanding stock options.
(4) Includes: (i) 367,472 shares of Sepracor Common Stock which Mr. Barberich
has the right to acquire within 60 days of January 31, 1999 upon exercise
of outstanding stock options; (ii) 30,000 shares of Sepracor Common Stock
held in trust for Mr. Barberich's daughter; (iii) 107 shares of Sepracor
Common Stock held by Mr. Barberich's wife; and (iv) 1,048 shares of
Sepracor Common Stock held by Mr. Barberich's daughter, as to which Mr.
Barberich disclaims beneficial ownership.
(5) Includes 356,300 shares of the Company's Common Stock which Mr. Vogel has
the right to acquire within 60 days after January 31, 1999 upon exercise of
outstanding stock options.
(6) Represents shares of Sepracor Common Stock that Mr. Vogel has the right to
acquire within 60 days after January 31, 1999 upon exercise of outstanding
stock options.
(7) Represents shares of the Company's Common Stock that each such person has
the right to acquire within 60 days after January 31, 1999 upon exercise of
outstanding stock options.
(8) Includes: (i) 141,000 shares of Sepracor Common Stock which Mr. Southwell
has the right to acquire within 60 days of January 31, 1999 upon exercise
of outstanding stock options; and (ii) 13,000 shares of Sepracor Common
Stock as to which Mr. Southwell's ex-wife, pursuant to a divorce decree,
can direct the sale and is entitled to the proceeds.
(9) Includes 80,000 shares of the Company's Common Stock that Mr. Boschetti has
the right to acquire within 60 days of January 31, 1999 upon exercise of
outstanding stock options.
(10) Excludes the 5,369,788 shares of Common Stock beneficially owned by
Sepracor, as to which shares each director and executive officer disclaims
beneficial ownership. Includes an aggregate of 655,080 shares of the
Company's Common Stock which all executive officers and directors have a
right to acquire within 60 days after January 31, 1999 upon exercise of
outstanding stock options.
(11) Includes an aggregate of 513,472 shares of Sepracor Common Stock which all
executive officers and directors have the right to acquire within 60 days
of January 31, 1999 upon exercise of outstanding stock options. As of
January 31, 1999, all directors and executive officers as a group owned
3.1% of the Sepracor Common Stock.
ELECTION OF DIRECTORS
The persons named in the enclosed proxy will vote to elect as directors the
eight nominees named below, unless the proxy is marked otherwise. If a
stockholder returns a proxy without contrary instructions the persons named as
proxies will vote to elect as directors the director nominees named below.
William E. Rich, currently a director, is not standing for re-election to the
Board of Directors.
Each director will be elected to hold office until the 2000 Annual Meeting
of Stockholders and until his successor is duly elected and qualified. All of
the nominees have indicated their willingness to serve, if elected; however, if
any nominee should be unable to serve, the shares of Common Stock represented by
proxies may be voted for a substitute nominee designated by the Board of
Directors.
3
<PAGE> 7
There are no family relationships between or among any officers or
directors of the Company.
Set forth below are the name and age of each member of the Board of
Directors, and the positions and offices held by him, his principal occupation
and business experience during the past five years, the names of other publicly
held companies of which he serves as a director and the year of the commencement
of his term as a director of the Company. Information with respect to the number
of shares of Common Stock beneficially owned by each director, directly or
indirectly, as of January 31, 1999, appears above under the heading "Stock
Ownership of Certain Beneficial Owners and Management."
NOMINEES FOR DIRECTOR
TIMOTHY J. BARBERICH, age 51, has served as a director of the Company since
its organization in 1993. Mr. Barberich was a founder of Sepracor, an emerging
speciality pharmaceutical company, and has served as President, Chief Executive
Officer and a director of Sepracor since January 1984. Sepracor owns
approximately 64% of the outstanding Common Stock of the Company. Mr. Barberich
also serves as a director of HemaSure Inc., a publicly traded company of which
Sepracor owns approximately 42% of the outstanding common stock ("HemaSure").
JOHN M. CARNUCCIO, age 45, is a nominee for director. From January 1999
until May 1999, Mr. Carnuccio served as Executive Vice President of the Company
and President of the Medical Products Business of BioSphere Medical. In May
1999, he was appointed President and Chief Executive Officer of the Company.
From 1979 to January 1999, Mr. Carnuccio served in a number of capacities at
Boston Scientific Corporation, a medical device company, most recently as Vice
President, Market Development, Interventional Gynecology, from April 1998 to
January 1999 and as Vice President and General Manager, Microvasive Urology
Division from 1992 to April 1998.
WILLIAM M. COUSINS, JR., age 74, has served as a director of the Company
since January 1994. Since 1974, Mr. Cousins has served as the President of
William M.. Cousins, Jr., Inc., a management consulting firm. Mr. Cousins is a
member of the Board of Directors of Alba Waldensian, Inc. and Wellco
Enterprises, Inc.
ALEXANDER M. KLIBANOV, PH.D., age 49, has served as a director of the
Company since January 1994. Since 1979, Dr. Klibanov has been a faculty member
of the Massachusetts Institute of Technology where he is currently Professor of
Chemistry and a member of the Biotechnology Process Engineering Center.
PAUL A. LOONEY, age 59, has served as a director of the Company since
January 1994. From 1984 to 1995, Mr. Looney served as President and Chief
Executive Officer of Corning Costar Corporation, a life science products company
and a wholly-owned subsidiary of Corning, Inc.
RICCARDO PIGLIUCCI, age 52, has served as a director of the Company since
August 1995. Since May 1998, Mr. Pigliucci has served as President and Chief
Executive Officer of Discovery Partners International, a life sciences company.
From February 1996 to April 1998, he served as Chief Executive Officer of Life
Sciences International P.L.C. From January 1966 to April 1995, Mr. Pigliucci
served in a number of capacities at Perkin-Elmer Corporation, a global life
sciences instrumentation company, most recently as President and Chief Operating
Officer. Mr. Pigliucci is a member of the Board of Directors of Dionex
Corporation.
DAVID P. SOUTHWELL, age 38, has served as a director of the Company since
January 1997. He has served as Executive Vice President, Chief Financial Officer
of Sepracor since October 1995 and served as Senior Vice President and Chief
Financial Officer of Sepracor from July 1994 to October 1995. From August 1988
until July 1994, Mr. Southwell was associated with Lehman Brothers, a securities
firm, in various positions with the investment banking division, including in
the position of Vice President.
4
<PAGE> 8
JEAN-MARIE VOGEL, age 48, served as President, Chief Executive Officer and
a director of the Company from September 1994 until May 1999. In May 1999, he
was appointed Chairman. From January 1994 to September 1994, Mr. Vogel served as
Executive Vice President and Chief Operating Officer of the Company. From 1992
to 1993, Mr. Vogel served as President of the European Operations of Cuno, Inc.,
a supplier of filtration processes, equipment and devices used in the production
of biological drugs and food products. From 1977 to 1992, Mr. Vogel served in
various capacities with Millipore Corporation ("Millipore"), a manufacturer of
membrane filtration-based products, in its international operations with
experience in Asia, Latin America, the former Soviet Union, the Middle East and
Australia, including as Vice President and General Manager of Millipore's Asian
operations. Mr. Vogel is a French citizen.
DIRECTOR NOT STANDING FOR REELECTION
WILLIAM E. RICH, PH.D., age 54, has served as a director of the Company
since its organization in December 1993. Since September 1994, Dr. Rich has
served as President and Chief Executive Officer of Ciphergen Biosystems, Inc., a
biotechnology company. From January 1994 to September 1994, Dr. Rich served as
President and Chief Executive Officer of the Company. From September 1991 to
January 1994, Dr. Rich served as Senior Vice President and General Manager,
Bioseparations of Sepracor.
BOARD AND COMMITTEE MEETINGS
The Company has a standing Audit Committee of the Board of Directors, which
provides the opportunity for direct contact between the Company's independent
accountants and the Board. The Audit Committee has responsibility for
recommending the appointment of the Company's independent accountants, reviewing
the scope and results of audits and reviewing the Company's internal accounting
control policies and procedures. The Audit Committee held one meeting in 1998.
The members of the Audit Committee are Mr. Cousins and Mr. Klibanov.
The Company also has a standing Compensation Committee of the Board of
Directors, which is responsible for determining the compensation of, and
establishing compensation policies for, the executive officers of the Company.
The Compensation Committee held one meeting during 1998. The members of the
Compensation Committee are Messrs. Cousins and Pigliucci. See "Report of the
Compensation Committee" below.
The Company does not have a nominating committee or a committee serving a
similar function. Nominations are made by and through the full Board of
Directors.
The Board of Directors held four meetings during 1998. Except for William
E. Rich, Ph.D., each director attended at least 75% of the total number of
meetings of the Board of Directors and all committees of the Board on which he
served.
COMPENSATION FOR DIRECTORS
Directors who are neither officers nor employees of the Company or of any
affiliate of the Company (the "Outside Directors") receive $1,000 for each
meeting of the Board they attend and are entitled to participate in the
Company's 1994 Director Stock Option Plan (the "Director Option Plan"), as
further described below. Directors who are officers or employees of the Company
or of any affiliate of the Company do not receive compensation for attendance at
meetings.
Under the Director Option Plan, options to purchase 10,000 shares of Common
Stock are granted to each Outside Director, except for Mr. Barberich who was
granted options to purchase 40,000 shares of Common Stock, upon his initial
election as a director (the "Initial Options") and options to purchase 2,000
shares of
5
<PAGE> 9
Common Stock are granted upon the dates on which the Outside Director is
subsequently reelected to the Board (the "Reelection Options").
Each Initial Option granted to a director under the Director Option Plan
vests in five equal annual installments beginning on the first anniversary of
the date of grant, and Reelection Options granted under the Director Option Plan
vest in two equal annual installments beginning on the first anniversary of the
date of grant. The exercise price per share will equal the fair market value of
a share of Common Stock on the date on which the option is granted, except that
the exercise price per share was $2.00 for any Initial Options granted prior to
January 15, 1994. The exercise price must be paid in cash. Options granted under
the Director Option Plan are not transferable by the director except by will or
by the laws of descent and distribution and are exercisable during the lifetime
of the director only while he or she is serving as a director of the Company or
within 90 days after he or she ceases to serve as a director of the Company. No
option is exercisable more than ten years from the date of grant. If a director
dies or becomes disabled while he or she is serving as a director of the
Company, the option is exercisable for a one year period thereafter.
The Board of Directors may suspend or discontinue the Director Option Plan
or amend it in any respect; provided, that, without the approval of the
stockholders, no amendment may change the number of shares subject to the
Director Option Plan, change the designation of the class of directors eligible
to receive options, or materially increase the benefits accruing to participants
under the Director Option Plan, and the Director Option Plan may not be amended
more than once in a six month period.
On May 26, 1998, options to purchase an aggregate of 14,000 shares of
Common Stock at an exercise price of $1.75 per share (the closing price of the
Common Stock on the Nasdaq Stock Market on the date of grant) were granted under
the Director Option Plan to each of the following directors: Mr. Barberich, Mr.
Cousins, Dr. Klibanov, Mr. Looney, Mr. Pigliucci, Dr. Rich and Mr. Southwell.
6
<PAGE> 10
COMPENSATION OF EXECUTIVE OFFICERS
Summary Compensation Table. The following table sets forth certain
information with respect to the annual and long-term compensation for the last
three fiscal years of the Company's President and Chief Executive Officer and
the Company's two other most highly-compensated executive officers whose total
annual salary and bonus for 1998 exceeded $100,000 (collectively, the "Named
Executive Officers").
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
-------------------------------------------- ------------
OTHER SECURITIES ALL OTHER
COMPENSATION UNDERLYING COMPENSATION
NAME AND PRINCIPAL POSITION YEAR SALARY ($) BONUS ($) ($) OPTIONS (#) ($)(1)
- --------------------------- ---- ---------- --------- ------------ ------------ ------------
<S> <C> <C> <C> <C> <C> <C>
Jean-Marie Vogel........... 1998 $163,803 $70,000 $0 0 $1,536
President and Chief 1997 163,803 15,000 0 420,000 3,038
Executive Officer 1996 163,803 15,000 0 0 1,251
Egisto Boschetti, Ph.D..... 1998 $132,658 $16,126 $0 0 $2,130
Executive Vice President 1997 131,455 7,288 0 60,000 5,691
and Chief Scientific 1996 133,213 17,443 0 10,000 3,992
Officer
Therese Bourdy............. 1998 $114,794 $10,568 $0 20,000 $2,169
Vice President of Media 1997 99,414 16,482 0 0 1,591
Operations 1996 102,022 16,127 0 25,000 1,812
</TABLE>
- ---------------
(1) Represents the taxable portion of group life insurance, retirement and other
benefits paid by the Company.
Option Grant Table. The following table sets forth certain information
regarding options granted during the year ended December 31, 1998 by the Company
to the Named Executive Officers.
OPTION GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS
------------------------------------------------
PERCENT OF POTENTIAL REALIZABLE
TOTAL VALUE AT ASSUMED
NUMBER OF OPTIONS ANNUAL RATES OF STOCK
SECURITIES GRANTED TO EXERCISE PRICE APPRECIATION FOR
UNDERLYING EMPLOYEES OR BASE OPTION TERM(1)
OPTIONS IN FISCAL PRICE EXPIRATION -----------------------
NAME GRANTED (#) YEAR ($/SH) DATE 5% ($) 10% ($)
---- ----------- ---------- -------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
Jean-Marie Vogel................ 0 --% -- -- -- --
Egisto Boschetti, Ph.D.......... 0 --% -- -- -- --
Therese Bourdy.................. 20,000(2) 9% $2.00 4/29/08 $25,200 $63,600
</TABLE>
- ---------------
(1) Amounts represent hypothetical gains that could be achieved for options if
exercised at the end of the option term. These gains are based on assumed
rates of stock price appreciation of 5% and 10% compounded annually from the
date options are granted. Actual gains, if any, on stock option exercises
will depend on the future performance of the Company's Common Stock on the
date on which options were exercised.
7
<PAGE> 11
(2) The option vests as to 4,000 shares on each of April 29, 1999, April 29,
2000, April 29, 2001, April 29, 2002, and April 29, 2003.
Year-End Option Values Table. The following table sets forth certain
information regarding stock options held as of December 31, 1998 by the Named
Executive Officers. None of the Named Executive Officers exercised any stock
options during the year ended December 31, 1998.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND
YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF VALUE OF
SECURITIES UNEXERCISED
UNDERLYING IN-THE-MONEY
UNEXERCISED OPTIONS AT FISCAL
OPTIONS AT FISCAL YEAR-END
YEAR-END (#) ($)(1)
NUMBER OF ----------------- -----------------
SHARES ACQUIRED VALUE UNEXERCISABLE/ UNEXERCISABLE/
NAME ON EXERCISE (#) REALIZED ($) EXERCISABLE EXERCISABLE
- ---- --------------- ------------ ----------------- -----------------
<S> <C> <C> <C> <C>
Jean-Marie Vogel................ -- -- 292,300/388,200 0/0
Egisto Boschetti, Ph.D.......... -- -- 68,000/67,000 0/0
Therese Bourdy.................. -- -- 20,200/41,800 0/0
</TABLE>
- ---------------
(1) Value is zero because the option exercise price in each case is greater than
the closing sales price of the Company's Common Stock as reported by the
Nasdaq National Market on December 31, 1998 ($.5938), the last trading day
of the Company's 1998 fiscal year.
EMPLOYMENT AGREEMENTS
Jean-Marie Vogel. In May 1999, the Company entered into an Employment
Agreement with Mr. Vogel pursuant to which he serves as Chairman of the Company.
The agreement has an initial term of two years and is subject to automatical
renewal unless either party elects not to renew in writing no less than 90 days
before the end of the term. Mr. Vogel is also entitled to participate in a bonus
program based upon quantitative and qualitative goals which are established by
agreement between the parties. The agreement may be terminated by either party
upon 30 days' prior notice, is terminable by the Company for Cause (as defined
therein) and by Mr. Vogel for Good Reason (as defined therein). In the event Mr.
Vogel is terminated for Cause or if Mr. Vogel elects to terminate or not renew
the agreement, he is entitled to receive salary and benefits through his last
day of employment. In the event Mr. Vogel is terminated without Cause, resigns
for Good Reason or the Company elects to not renew the agreement, he shall be
entitled to receive (i) 200% of his base salary in effect at the time of
termination, and two times the average bonus paid or awarded to him in the
24-month period prior to termination, such amounts to be paid over a 24-month
period, (ii) benefits, for a period of up to 24 months, substantially similar to
those he was receiving at the time of termination, and (iii) an extension of the
exercise period of all vested options from three months to 36 months. In
addition, during any time after termination of employment in which Mr. Vogel is
accepting the payments and benefits described in the preceeding sentence, he
agrees not to compete with the Company, hire or recruit its employs or divert
away business, subject to certain conditions.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Based solely on its review of copies of reports filed by all officers and
directors of the Company who are persons required to file reports ("Reporting
Persons") pursuant to Section 16(a) of the Securities Exchange
8
<PAGE> 12
Act of 1934, as amended (the "Exchange Act"), or written representations from
certain Reporting Persons, the Company believes that during fiscal 1998 all
filings required to be made by its Reporting Persons were timely made in
accordance with the requirements of the Exchange Act with the exception of a
report on Form 3 (Initial Statement of Beneficial Ownership) that was filed late
by Philip V. Holberton, the Chief Financial Officer of the Company.
REPORT OF THE COMPENSATION COMMITTEE
The Compensation Committee of the Company, which is currently comprised of
two non-employee directors, William M. Cousins, Jr. and Riccardo Pigliucci, is
responsible for determining the compensation package of each executive officer.
The Compensation Committee sets the compensation for executive officers and
establishes compensation policies for the Company's Chief Executive Officer and
the other executive officers of the Company, including the Named Executive
Officers.
The Company's executive compensation program is designed to promote the
achievement of the Company's business goals, and, thereby, to maximize corporate
performance and stockholder returns. Executive compensation generally consists
of a combination of base salary, cash bonuses and stock-based incentives. The
Compensation Committee considers stock incentives to be a critical component of
an executive's compensation package in order to help align executive interests
with stockholder interests.
Compensation Philosophy
The objectives of the executive compensation program are to align
compensation with business objectives and individual performance, and to enable
the Company to attract, retain and reward executive officers who are expected to
contribute to the long-term success of the Company. The Company's executive
compensation philosophy is based on the principles of competitive and fair
compensation and sustained performance.
- COMPETITIVE AND FAIR COMPENSATION
The Company is committed to providing an executive compensation program
that helps attract and retain highly qualified executives. To ensure that
compensation is competitive, the Company compares its compensation practices
with those of other companies in the industry and sets its compensation
guidelines based on this review. The Company believes compensation for its
executive officers is within the range of compensation paid to executives with
comparable qualifications, experience and responsibilities in the same or
similar business and of comparable size and success. The Company also strives to
achieve equitable relationships both among the compensation of individual
officers and between the compensation of officers and other employees throughout
the organization.
- SUSTAINED PERFORMANCE
Executive officers are rewarded based upon corporate performance and
individual performance. Corporate performance is evaluated by reviewing the
extent to which strategic and business plan goals are met, including such
factors as achievement of operating budgets, establishment of strategic
licensing and development alliances with third parties, timely development and
commercial introduction of new processes and products and performance relative
to competitors. Individual performance is evaluated by reviewing attainment of
specified individual objectives and the degree to which teamwork and Company
values are fostered.
9
<PAGE> 13
In evaluating each executive officer's performance, the Company generally
conforms to the following process:
- Company and individual goals and objectives generally are set at the
beginning of the performance cycle.
- At the end of the performance cycle, the accomplishment of the
executive's goals and objectives and his contributions to the Company are
evaluated.
- The executive's performance is then compared with peers within the
Company and the results are communicated to the executive.
- The comparative results, combined with comparative compensation practices
of other companies in the industry, is then used to determine salary and
stock compensation levels.
The salary for executives is generally set by reviewing compensation for
competitive positions in the market and the historical compensation levels of
the executives. Increases in annual salaries and payment of bonus awards is
based on actual corporate and individual performance against targeted
performance and various subjective performance criteria. Targeted performance
criteria vary for each executive based on his area of responsibility, and may
include achievement of the operating budget for the Company as a whole or of a
business group of the Company, continued innovation in development and
commercialization of the Company's technology and products, timely development
and commercial introduction of new products or processes, implementation of
financing strategies and establishment of strategic licensing and development
alliances with third parties. Subjective performance criteria include an
executive's ability to motivate others, develop the skills necessary to grow as
the Company matures, recognize and pursue new business opportunities and
initiate programs to enhance the Company's growth and success. The Committee
does not use a specific formula based on these targeted performance and
subjective criteria, but instead makes an evaluation of each executive officer's
contributions in light of all such criteria.
Compensation at the executive officer level also includes the long-term
incentives afforded by stock options. The stock option program is designed to
promote the identity of long-term interests between the Company's employees and
its shareholders and assist in the retention of executives. The size of option
grants is generally intended to reflect the executive's position with the
Company and his contributions to the Company, including his success in achieving
the individual performance criteria described above. The option program
generally uses a five-year vesting period to encourage key employees to continue
in the employ of the Company. All stock options granted to executive officers in
1998 were granted at fair market value on the date of grant. During 1998,
Therese Bourdy received options to purchase an aggregate of 20,000 shares of
Common Stock, at a weighted average exercise price of $2.00 per share and Philip
V. Holberton received options to purchase an aggregate of 24,000 shares of
Common Stock, at a weighted average exercise price of $1.313.
Executive officers are also eligible to participate in the Company's 1997
Employee Stock Purchase Plan (the "Purchase Plan"). The Purchase Plan is
available to virtually all employees of the Company and generally permits
participants to purchase shares at a discount of approximately 15% from the fair
market value at the beginning or end of the applicable purchase period.
Compliance with Internal Revenue Code Section 162(m). Section 162(m) of
the Internal Revenue Code of 1986, as amended (the "Code"), enacted in 1993,
generally disallows a tax deduction to public companies for compensation over
$1.0 million paid to the corporation's Chief Executive Officer and four other
most highly compensated executive officers. Qualifying performance compensation
will not be subject to the deduction limit if certain requirements are met.
While the Company has not structured its 1997 Stock Incentive Plan to meet the
requirements for exclusion from the deduction limit of Section 162(m), the
10
<PAGE> 14
Company generally intends to structure the performance-based portion of the
compensation of its executive officers in a manner that complies with the
statute to mitigate any disallowance of deductions.
Mr. Vogel's 1998 Compensation
Mr. Vogel is eligible to participate in the same executive compensation
plans available to the other executive officers of the Company. The Compensation
Committee believes that Mr. Vogel's annual compensation, including the portion
of his compensation based upon the Company's stock option program, has been set
at a level competitive with other companies in the industry.
Mr. Vogel's salary for 1998 was $163,803. His salary for 1998 remained
unchanged from 1997. Mr. Vogel received bonus compensation of $70,000 for his
1998 performance. Mr. Vogel's 1998 salary and bonus were based upon a number of
factors, which included his progress in further developing and implementing the
Company's long term strategic plan, primarily focusing on the sale of the
operating assets for the process media business and the continued development of
the Company's technology related to microspheres and its application for
embolization. In establishing Mr. Vogel's salary for 1998, the Compensation
Committee also reviewed a number of national compensation surveys for comparable
positions in similar industries.
Compensation Committee
William M. Cousins, Jr.
Riccardo Pigliucci
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The current members of the Compensation Committee are Messrs. Cousins and
Pigliucci. Neither member of the Compensation Committee was at any time during
1998, or formerly, an officer or employee of the Company or any subsidiary of
the Company, nor has any member of the Compensation Committee had any
relationship with the Company requiring disclosure under Item 404 of Regulation
S-K under the Exchange Act.
No executive officer of the Company has served as a director or member of
the Compensation Committee (or other committee serving an equivalent function)
of any other entity, one of whose executive officers served as a director of or
member of the Compensation Committee of the Company.
11
<PAGE> 15
COMPARATIVE STOCK PERFORMANCE
The Common Stock of BioSphere Medical (formerly BioSepra Inc.) traded on
the Nasdaq National Market from March 25, 1994 through January 13, 1999, at
which time it began trading on the National Association of Securities Dealers,
Inc. OTC Bulletin Board. The comparative stock performance graph below compares
the cumulative stockholder return on the Common Stock of the Company for the
period from March 25, 1994 through December 31, 1998 with the cumulative total
return on (i) the Nasdaq Stock Market (US Companies) and (ii) the Nasdaq
Pharmaceuticals Stocks (assuming the investment of $100 in the Company's Common
Stock (at the initial public offering price), the Nasdaq Stock Market and the
Nasdaq Pharmaceuticals Stocks on March 25, 1994 and reinvestment of all
dividends). Measurement points are on March 25, 1994 and the last trading day of
the years ended December 31, 1994, December 31, 1995, December 31, 1996,
December 31, 1997 and December 31, 1998. Prior to March 25, 1994, the Company's
Common Stock was not registered under the Exchange Act.
[STOCK PERFORMANCE GRAPH]
<TABLE>
<CAPTION>
BIOSPHERE MEDICAL,
INC.|(FORMERLY BIOSEPRA NASDAQ STOCK MARKET (US NASDAQ PHARMACEUTICALS
INC.) COMPANIES) STOCKS
----------------------- ----------------------- ----------------------
<S> <C> <C> <C>
3/25/94 100.00 100.00 100.00
12/94 45.00 96.80 87.00
12/95 45.00 136.90 159.70
12/96 31.70 168.40 160.10
12/97 23.30 206.50 165.40
12/98 7.90 290.00 210.40
</TABLE>
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The Company was organized in December 1993 as a subsidiary of Sepracor.
Effective January 1, 1994, Sepracor transferred its chromatography business,
including all of the outstanding shares of IBF, a subsidiary of Sepracor, to the
Company in exchange for 4,000,000 shares of Common Stock. In June 1996, Sepracor
converted the outstanding principal and interest of a loan to BioSphere Medical
into an aggregate of 1,369,788 shares of Sepracor's Common Stock. Currently,
Sepracor owns approximately 64% of the Company's Common Stock. Under applicable
provisions of the Delaware General Corporation Law, Sepracor has the ability,
acting alone, to approve any action requiring approval of the holders of a
majority of the outstanding shares of Common Stock. Mr. Barberich and Mr.
Southwell, directors of the Company, are President and Chief Executive Officer
and Executive Vice President and Chief Financial Officer, respectively, of
Sepracor.
12
<PAGE> 16
Technology Transfer and License Agreement. In January 1994, the Company
and Sepracor entered into a Technology Transfer and License Agreement (the
"Technology Transfer Agreement") pursuant to which Sepracor transferred to the
Company all technology owned or controlled by Sepracor, including trade secrets,
patents and patent applications, that relates to and is used in researching,
developing or manufacturing products in the "Company Field." The Company Field
means generally the separation of biological molecules. The Technology Transfer
Agreement expired on January 1, 1998. The Company has granted to Sepracor a
perpetual, royalty-free, exclusive license to the transferred technology for the
development, manufacture, use or sale of any products within the field of chiral
synthesis, chiral separations and the development, manufacture, use or sale of
chiral drugs and chiral drug intermediates (the "Sepracor Field"), as well as a
non-exclusive license to the transferred technology for the development,
manufacture, use or sale of any products outside the Company Field. In addition,
Sepracor granted a perpetual, royalty-free, exclusive license to the Company for
any improvements to the transferred technology useful in the Company Field which
are developed or otherwise acquired by Sepracor during the term of the
Technology Transfer ("Improvements"). Although the licenses granted by Sepracor
to the Company terminated when the Technology Transfer Agreement expired, it
provided that any licenses granted during the term survived to the extent they
relate to Improvements existing on the date of termination.
Corporate Services Agreement. The Company and Sepracor entered into a
one-year Corporate Services Agreement dated as of January 1, 1994, which
provides for a monthly fee to be paid by the Company for basic services, such as
accounting, human resources support services, data processing and laboratory
support services provided by Sepracor. This fee was determined by estimating
Sepracor's cost of the Company's expected usage of such basic services. The
Company may purchase additional services from Sepracor for a fixed rate based on
the number of hours spent by each Sepracor employee providing such services. For
items with identifiable costs such as insurance coverage, Sepracor charges the
Company based upon costs directly attributable to the Company. Management
believes that the charges under the Corporate Services Agreement are reasonable
and that the terms of the Corporate Services Agreement are at least as favorable
to the Company as the terms that could be obtained from an unaffiliated third
party. This Agreement had an initial term of one year and has been extended by
the Company for three additional one-year terms. The Company and Sepracor
continue to operate under the terms of the original agreement. Sepracor retains
the right to decline to provide any services which cause an unreasonable burden
to Sepracor. The Agreement permits the Company to terminate at any time
following 60 days' notice to Sepracor, and automatically terminates six months
after Sepracor's ownership percentage of the Company decreases to less than 50%
of the Company's issued and outstanding shares. The aggregate payments made by
the Company to Sepracor for basic services under this Agreement were $208,000 in
1996, $208,000 in 1997 and $155,000 in 1998.
Sublease Agreements. Sepracor has entered into a Sublease Agreement with
the Company under which Sepracor subleases a portion of its facilities in
Marlborough, Massachusetts to the Company. The amount payable to Sepracor under
the Sublease Agreement is equal to Sepracor's rental costs under its lease
allocable to the portion of the premises subleased to the Company plus a pro
rata allocation of the estimated facility maintenance, utilities and other
operating costs. The rental payment made to Sepracor by the Company under this
Agreement was approximately $72,000 in 1996, $93,000 in 1997 and $81,000 in
1998. Operating costs under this Agreement were approximately $233,000 in 1996,
$277,000 in 1997 and $167,000 in 1998.
Registration Rights. Sepracor has certain registration rights with respect
to its shares in the Company as provided in the Technology Transfer Agreement.
Promissory Note. In January 1996, the Company entered into a Promissory
Note for $350,000, or so much of such sum as shall have been advanced by
Sepracor. This amount is payable to Sepracor over sixty monthly installments and
does not bear interest. As of December 31, 1998, $163,600 was outstanding under
this Promissory Note.
13
<PAGE> 17
Guaranteed Indebtedness. The Company has indebtedness outstanding of
$402,000 as of December 31, 1999 under a French Franc loan that is guaranteed by
Sepracor. Additionally, the Company's $3,000,000 line of credit with a U.S.
bank, of which $2,000,000 is outstanding as of December 31, 1998, is guaranteed
by Sepracor.
APPROVAL OF AMENDMENT TO THE COMPANY'S
RESTATED CERTIFICATE OF INCORPORATION
On January 29, 1999, the Board of Directors adopted, subject to stockholder
approval, an amendment to the Company's Certificate of Incorporation, as
amended, providing for an increase from 12,000,000 to 25,000,000 in the number
of authorized shares of Common Stock (the "Charter Amendment"). As of March 31,
1999, the Company had a total of approximately 8,456,059 shares of Common Stock
outstanding and 2,350,000 shares of Common Stock reserved for issuance upon
conversion of stock options outstanding under its stock option and stock
purchase plans.
If the Charter Amendment is approved, the additional authorized shares of
Common Stock would be available for issuance in the future for corporate
purposes, including without limitation, stock splits, stock dividends,
financings, acquisitions, and management incentive and employee benefit plans,
as the Board of Directors may deem advisable, without the necessity of further
stockholder action. The issuance of additional shares of Common Stock, while
providing desirable flexibility in connection with possible acquisitions and
other corporate purposes, would have the effect of diluting the Company's
current stockholders and could have the effect of making it more difficult for a
third party to acquire, or of discouraging a third party from attempting to
acquire, control of the Company. Other than in connection with its existing
stock option plans and upon sale of shares purchased pursuant to employee stock
purchase plans, the Company has no present intention or plans to issue any
shares of Common Stock.
BOARD RECOMMENDATION
THE BOARD OF DIRECTORS BELIEVES THAT THE APPROVAL OF THE CHARTER AMENDMENT
INCREASING THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK IS IN THE BEST
INTERESTS OF THE COMPANY AND ITS STOCKHOLDERS AND THEREFORE RECOMMENDS A VOTE
FOR THIS PROPOSAL.
APPROVAL OF AMENDMENT TO 1997 STOCK INCENTIVE PLAN
On January 29, 1999, the Company's Board of Directors adopted, subject to
stockholder approval, an amendment to the Company's 1997 Stock Incentive Plan
(the "1997 Plan") increasing the number of shares of Common Stock authorized for
issuance under the 1997 Plan from 1,000,000 to 3,150,000. The Board of Directors
believes that stock awards have been, and will continue to be, an important
element in attracting and maintaining key employees and directors who are
expected to contribute to the Company's growth and success. If the amendment is
approved, the Company will have additional authorized shares of Common Stock
available for future awards, including awards in connection with any merger,
consolidation or acquisition by the Company.
DESCRIPTION OF AWARDS
The 1997 Plan provides for the grant of options intended to qualify as
incentive stock options under Section 422 of the Code, nonstatutory stock
options, restricted stock awards and other stock-based awards, including the
grant of shares based upon certain conditions, the grant of securities
convertible into Common Stock and the grant of stock appreciation rights
(collectively "Awards").
14
<PAGE> 18
Incentive Stock Options and Nonstatutory Stock Options. Optionees receive
the right to purchase a specified number of shares of Common Stock at some time
in the future at a specified option price and subject to such other terms and
conditions as are specified in connection with the option grant. Options may be
granted at an exercise price which may be less than, equal to or greater than
the fair market value of the Common Stock on the date of grant. Under present
law, however, incentive stock options may not be granted at an exercise price
less than the fair market value of the Common Stock on the date of grant (or
less than 110% of the fair market value in the case of incentive stock options
granted to optionees holding 10% or more of the voting power of the Company).
Options may not be granted for a term in excess of ten years. The 1997 Plan
permits the Board to determine the manner of payment of the exercise price of
options, including through payment by cash, check or in connection with a
"cashless exercise" through a broker, by surrender to the Company of shares of
Common Stock, by delivery to the Company of a promissory note, or by any other
lawful means.
Restricted Stock Awards. Restricted stock awards entitle recipients to
acquire shares of Common Stock, subject to the right of the Company to
repurchase all or part of such shares from the recipient in the event that the
conditions specified in the applicable Award are not satisfied prior to the end
of the applicable restriction period established for such Award.
Other Stock-Based Awards. Under the 1997 Plan, the Board has the right to
grant other Awards based upon the Common Stock having such terms and conditions
as the Board may determine, including the grant of shares based upon certain
conditions, the grant of securities convertible into Common Stock and the grant
of stock appreciation rights.
ELIGIBILITY TO RECEIVE AWARDS
Officers, employees, directors, consultants and advisors of the Company and
its subsidiaries are eligible to be granted Awards under the 1997 Plan. Under
present law, however, incentive stock options may only be granted to employees.
As of March 31, 1999, approximately 48 persons were eligible to receive
Awards under the 1997 Plan, including the Company's three executive officers and
seven non-employee directors. The granting of Awards under the 1997 Plan is
discretionary, and the Company cannot now determine the number or type of Awards
to be granted in the future to any particular person or group.
On March 31, 1999, the last reported sale price of the Company's Common
Stock on the OTC Bulletin Board was $0.97.
ADMINISTRATION
The 1997 Plan is administered by the Board of Directors. The Board has the
authority to adopt, amend and repeal the administrative rules, guidelines and
practices relating to the 1997 Plan and to interpret the provisions of the 1997
Plan. Pursuant to the terms of the 1997 Plan, the Board of Directors may
delegate authority under the 1997 Plan to one or more committees of the Board,
and subject to certain limitations, to one or more executive officers of the
Company. Subject to any applicable limitations contained in the 1997 Plan, the
Board of Directors or any other committee or executive officer to whom the Board
delegates authority, including the Compensation Committee, as the case may be,
selects the recipients of Awards and determines: (i) the number of shares of
Common Stock covered by options and the dates upon which such options become
exercisable; (ii) the exercise price of options; (iii) the duration of options;
and (iv) the number of shares of Common Stock subject to any restricted stock or
other stock-based Awards and the terms and conditions of such Awards, including
conditions for repurchase, issue price and repurchase price.
15
<PAGE> 19
The Board of Directors is required to make appropriate adjustments in
connection with the 1997 Plan and any outstanding Awards to reflect stock
dividends, stock splits and certain other events. In the event of a merger,
liquidation or other Acquisition Event (as defined in the 1997 Plan), the Board
of Directors is authorized to provide for outstanding Awards to be assumed or
substituted for, to accelerate the Awards to make them fully exercisable prior
to consummation of the Acquisition Event or to provide for a cash out of the
value of any outstanding options, provided, however, that any outstanding Awards
held by employees of the Company shall become immediately fully exercisable. If
any Award expires or is terminated, surrendered, canceled or forfeited, the
unused shares of Common Stock covered by such Award will again be available for
grant under the 1997 Plan.
AMENDMENT OR TERMINATION
No Award may be made under the 1997 Plan after March 28, 2007, but Awards
previously granted may extend beyond that date. The Board of Directors may at
any time amend, suspend or terminate the 1997 Plan.
FEDERAL INCOME TAX CONSEQUENCES
The following is a summary of the United States federal income tax
consequences that generally will arise with respect to Awards granted under the
1997 Plan and with respect to the sale of Common Stock acquired under the 1997
Plan.
Incentive Stock Options. In general, a participant will not recognize
taxable income upon the grant or exercise of an incentive stock option. Instead,
a participant will recognize taxable income with respect to an incentive stock
option only upon the sale of Common Stock acquired through the exercise of the
option ("ISO Stock"). The exercise of an incentive stock option may, however,
subject the participant to the alternative minimum tax.
Generally, the tax consequences of selling ISO Stock will vary with the
length of time that the participant has owned the ISO Stock at the time it is
sold. If the participant sells ISO Stock after having owned it for at least two
years from the date the option was granted (the "Grant Date") and one year from
the date the option was exercised (the "Exercise Date"), then the participant
will recognize long-term capital gain in an amount equal to the excess of the
sale price of the ISO Stock over the exercise price.
If the participant sells ISO Stock for more than the exercise price prior
to having owned it for at least two years from the Grant Date and one year from
the Exercise Date (a "Disqualifying Disposition"), then all or a portion of the
gain recognized by the participant will be ordinary compensation income and the
remaining gain, if any, will be a capital gain. This capital gain will be a
long-term capital gain if the participant has held the ISO Stock for more than
one year prior to the date of sale.
If a participant sells ISO Stock for less than the exercise price, then the
participant will recognize capital loss equal to the excess of the exercise
price over the sale price of the ISO Stock. This capital loss will be a
long-term capital loss if the participant has held the ISO Stock for more than
one year prior to the date of sale.
Nonstatutory Stock Options. As in the case of an incentive stock option, a
participant will not recognize taxable income upon the grant of a nonstatutory
stock option. Unlike the case of an incentive stock option, however, a
participant who exercises a nonstatutory stock option generally will recognize
ordinary compensation income in an amount equal to the excess of the fair market
value of the Common Stock acquired through the exercise of the option ("NSO
Stock") on the Exercise Date over the exercise price.
With respect to any NSO Stock, a participant will have a tax basis equal to
the exercise price plus any income recognized upon the exercise of the option.
Upon selling NSO Stock, a participant generally will recognize capital gain or
loss in an amount equal to the difference between the sale price of the NSO
Stock
16
<PAGE> 20
and the participant's tax basis in the NSO Stock. This capital gain or loss will
be a long-term gain or loss if the participant has held the NSO stock for more
than one year prior to the date of the sale.
Restricted Stock Awards. A participant will not recognize taxable income
upon the grant of a restricted stock Award, unless the participant makes an
election under Section 83(b) of the Code (a "Section 83(b) Election"). If the
participant makes a Section 83(b) Election within 30 days of the date of the
grant, then the participant will recognize ordinary compensation income, for the
year in which the Award is granted, in an amount equal to the difference between
the fair market value of the Common Stock at the time the Award is granted and
the purchase price paid for the Common Stock. If a Section 83(b) Election is not
made, the participant will recognize ordinary compensation income, at the time
that the forfeiture provisions or restrictions on transfer lapse, in an amount
equal to the difference between the fair market value of the Common Stock at the
time of such lapse and the original purchase price paid for the Common Stock.
The participant will have a basis in the Common Stock acquired equal to the sum
of the price paid and the amount of ordinary compensation income recognized.
Upon the disposition of the Common Stock acquired pursuant to a restricted
stock Award, the participant will recognize a capital gain or loss equal to the
difference between the sale price of the Common Stock and the participant's tax
basis in the Common Stock. The gain or loss will be a long-term capital gain or
loss if the shares are held for more than one year. For this purpose, the
holding period shall begin just after the date on which the forfeiture
provisions or restrictions lapse if a Section 83(b) Election is not made, or
just after the Award is granted if a Section 83(b) Election is made.
Other Stock-Based Awards. The tax consequences associated with any other
stock-based Award granted under the 1997 Plan will vary depending on the
specific terms of such Award, including, whether or not the Award has a readily
ascertainable fair market value, whether or not the Award is subject to
forfeiture provisions or restrictions on transfer, the nature of the property to
be received by the participant under the Award, the applicable holding period
and the participant's tax basis.
Tax Consequences to the Company. The grant of an Award under the 1997 Plan
will have no tax consequences to the Company. Moreover, in general, neither the
exercise of an incentive stock option nor the sale of any Common Stock acquired
under the 1997 Plan will have any tax consequences to the Company. The Company
generally will be entitled to a business-expense deduction, however, with
respect to any ordinary compensation income recognized by a participant under
the 1997 Plan, including as a result of the exercise of a nonstatutory stock
option, a Disqualifying Disposition or a Section 83(b) Election. Any such
deduction will be subject to the limitations of Section 162(m) of the Code.
BOARD RECOMMENDATION
THE BOARD OF DIRECTORS BELIEVES THE APPROVAL OF THE AMENDMENT TO THE 1997
PLAN IS IN THE BEST INTERESTS OF THE COMPANY AND ITS STOCKHOLDERS AND THEREFORE
IT RECOMMENDS A VOTE FOR THIS PROPOSAL.
INDEPENDENT ACCOUNTANTS
The Board of Directors, on the recommendation of its Audit Committee, has
selected the firm of Arthur Andersen LLP as the Company's independent
accountants for the current year. Arthur Andersen LLP has served as the
Company's independent accountants since January 1, 1996. Representatives of
Arthur Andersen LLP are expected to be present at the Annual Meeting. They will
have the opportunity to make a statement if they desire to do so and will also
be available to respond to appropriate questions from stockholders.
17
<PAGE> 21
OTHER MATTERS
The Board of Directors does not know of any other matters which may come
before the meeting. However, if any other matters are properly presented to the
meeting, it is the intention of the persons named in the accompanying proxy to
vote, or otherwise act, in accordance with their judgment on such matters.
All costs of solicitation of proxies will be borne by the Company. In
addition to solicitations by mail, the Company's directors, officers and regular
employees, without additional remuneration, may solicit proxies by telephone,
telegraph and personal interviews. Brokers, custodians and fiduciaries will be
requested to forward proxy soliciting material to the owners of stock held in
their names, and the Company will reimburse them for their reasonable
out-of-pocket expenses incurred in connection with the distribution of proxy
materials.
DEADLINE FOR SUBMISSION OF STOCKHOLDER PROPOSALS FOR THE 2000 ANNUAL MEETING
Proposals of stockholders intended to be presented at the 2000 Annual
Meeting of Stockholders must be received by the Company at its principal office
in Marlborough, Massachusetts not later than January 26, 2000 for inclusion in
the proxy statement for that meeting.
In order to be considered timely for purposes of Rule 14a-4, unless the
date for the 2000 Annual Meeting of Stockholders changes by more than 30 days
from the date of the 1999 Annual Meeting of Stockholders, any written notice of
a shareholder proposal must be received by the Company a reasonable time prior
to mailing of the proxy materials for the 2000 Annual Meeting of Stockholders.
Written notice of shareholder proposals submitted outside the processes of Rule
14a-8 for consideration at the 2000 Annual Meeting of Stockholders must be
received by the Company at least 45 days prior to the first anniversary of the
mailing of this year's proxy material. The persons designated in the Company's
proxy statement shall be granted discretionary authority with respect to any
shareholder proposals of which the Company does not receive timely notice.
By Order of the Board of Directors,
PHILIP V. HOLBERTON, Secretary
May 26, 1999
THE BOARD OF DIRECTORS ENCOURAGES STOCKHOLDERS TO ATTEND THE MEETING.
WHETHER OR NOT YOU PLAN TO ATTEND, YOU ARE URGED TO COMPLETE, DATE, SIGN AND
RETURN THE ENCLOSED PROXY IN THE ACCOMPANYING ENVELOPE. A PROMPT RESPONSE WILL
GREATLY FACILITATE ARRANGEMENTS FOR THE MEETING AND YOUR COOPERATION WILL BE
APPRECIATED. STOCKHOLDERS WHO ATTEND THIS MEETING MAY VOTE THEIR STOCK
PERSONALLY EVEN THOUGH THEY HAVE SENT IN THEIR PROXIES.
18
<PAGE> 22
APPENDIX A
BIOSPHERE MEDICAL, INC.
PROXY SOLICITED BY THE BOARD OF DIRECTORS
Annual Meeting of Stockholders - June 16, 1999
Those signing on the reverse side, revoking any prior proxies, hereby
appoint(s) Jean-Marie Vogel and Timothy J. Barberich, or each or any of them
with full power of substitution, as proxies for those signing on the reverse
side to act and vote at the 1999 Annual Meeting of Stockholders of BioSphere
Medical, Inc., and at any adjournments thereof as indicated upon all matters
referred to on the reverse side and described in the Proxy Statement for the
Meeting, and, in their discretion, upon any other matters which may properly
come before the Meeting.
THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED IN THE MANNER DIRECTED
BY THE UNDERSIGNED STOCKHOLDER(S). IF NO OTHER INDICATION IS MADE, THE PROXIES
SHALL VOTE "FOR" PROPOSAL NUMBERS 1, 2, 3 AND 4.
A VOTE FOR THE DIRECTOR NOMINEES AND FOR PROPOSAL NUMBERS 2, 3 AND 4 IS
RECOMMENDED BY THE BOARD OF DIRECTORS.
PLEASE VOTE, DATE, AND SIGN ON THE OTHER SIDE AND RETURN PROMPTLY IN THE
ENCLOSED ENVELOPE.
<PAGE> 23
Please date, sign and mail your proxy
card back as soon as possible!
Annual Meeting of Stockholders
BIOSPHERE MEDICAL, INC.
June 16, 1999
- --------------------------------------------------------------------------------
A [X] Please mark your
votes as in this
example
FOR all nominees WITHHOLD
listed at right AUTHORITY to
(except as marked vote for all nominees
to the contrary) listed at right
1) Election of
Directors [ ] [ ]
Nominees: Jean-Marie Vogel
Timothy J. Barberich
William M. Cousins, Jr.
Alexander M. Klibanov, Ph.D.
Paul A. Looney
Riccardo A. Pigliucci
John M. Carnuccio
David P. Southwell
INSTRUCTIONS: To withhold authority to vote for individual nominee(s) mark the
"FOR" box and strike a line through each such nominee(s) name in the list at the
right. Your shares will be voted for the remaining nominee(s).
2) Approval of an amendment to the FOR AGAINST ABSTAIN
Company's Certificate of Incorporation
increasing from 12,000,000 to 25,000,000 the
number of authorized shares of common
stock. [ ] [ ] [ ]
3) Approval of an amendment to the
Company's 1997 Stock Incentive Plan
increasing from 1,000,000 to 3,150,000 the
number of shares of common stock
reserved for issuance thereunder. [ ] [ ] [ ]
4) To transact such other business as may
properly come before the meeting or any
adjournment thereof. [ ] [ ] [ ]
Please read the reverse side of this card.
HAS YOUR ADDRESS CHANGED? DO YOU HAVE ANY COMMENTS?
- ----------------------------------- ------------------------------------
- ----------------------------------- ------------------------------------
- ----------------------------------- ------------------------------------
PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY USING THE
ENCLOSED ENVELOPE.
Signature________________________________________ Date:____________________
Signature_________________________________________ Date:_____________________
Note: Please sign this proxy exactly as your name appears hereon. Joint owners
should each sign personally. Trustees and other fiduciaries should indicate the
capacity in which they sign. If a corporation or partnership, this signature
should be that of an authorized officer who should state his or her title.
- --------------------------------------------------------------------------------
